Connection

Jean-Christophe Lagier to Drug Repositioning

Back to Details
This is a "connection" page, showing publications Jean-Christophe Lagier has written about Drug Repositioning.
Jean-Christophe Lagier
Connection Strength
0.072
Drug Repositioning
  1. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. Int J Antimicrob Agents. 2021 Jan; 57(1):106243.
    View in: PubMed
    Score: 0.014
  2. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients. Int J Antimicrob Agents. 2021 Jan; 57(1):106236.
    View in: PubMed
    Score: 0.014
  3. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. Int J Antimicrob Agents. 2021 Jan; 57(1):106239.
    View in: PubMed
    Score: 0.014
  4. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19. Int J Antimicrob Agents. 2021 Jan; 57(1):106238.
    View in: PubMed
    Score: 0.014
  5. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19. Int J Antimicrob Agents. 2021 Jan; 57(1):106242.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.